Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
D000281:Administration, Intranasal; D000282:Administration, Intravaginal; D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage; D002452:Cell Count; D004848:Epithelium / Q000276:immunology / Q000821:virology; D005260:Female; D017950:Ganglia, Sensory / Q000821:virology; D005836:Genitalia, Female / Q000276:immunology* / Q000821:virology; D006558:Herpes Genitalis / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D018258:Herpesvirus 2, Human / Q000201:enzymology / Q000276:immunology*; D007116:Immunization, Passive; D007148:Immunoglobulin mu-Chains / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology*; D013937:Thymidine Kinase / Q000172:deficiency; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D007148:Immunoglobulin mu-Chains; D014765:Viral Vaccines; D013937:Thymidine Kinase